Skip to main content

Advertisement

SpringerLink
Log in

The validation and clinical significance of LPCAT1 down-regulation in acute myeloid leukemia

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

Overexpression of lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been found in various solid cancers and is associated with disease progression, metastasis, and recurrence. However, the expression pattern of LPCAT1 in acute myeloid leukemia (AML) bone marrow remains unknown. The present study aimed to compare LPCAT1 expression differences in bone marrow samples from AML patients and healthy controls and assess the clinical relevance of LPCAT1 in AML.

Methods and results

LPCAT1 expression in bone marrow was significantly lower in AML than in healthy controls predicted by public databases. Furthermore, real-time quantitative PCR (RQ-PCR) validated that LPCAT1 expression in bone marrow was significantly down-regulated in AML compared to healthy controls [0.056 (0.000–0.846) vs 0.253 (0.031–1.000)]. The DiseaseMeth version 2.0 and The Cancer Genome Atlas analysis revealed that the LPCAT1 promoter was hypermethylated in AML, and there was a strong negative correlation between LPCAT1 expression and methylation (R = − 0.610, P < 0.001). RQ-PCR revealed that the frequency of LPCAT1 low expression was lower in the FAB-M4/M5 subtype than in the other subtypes (P = 0.018). The ROC curve revealed that LPCAT1 expression could serve as a potential diagnostic marker for differentiating AML from controls with an area under the ROC curve of 0.819 (95% CI 0.743–0.894, P < 0.001). In cytogenetically normal AML, patients with LPCAT1 low expression had significantly longer overall survival than those without LPCAT1 low expression (median 19 versus 5.5 months, P = 0.036).

Conclusions

LPCAT1 is down-regulated in AML bone marrow, and LPCAT1 down-regulation could be used as a potential biomarker for AML diagnosis and prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

References

  1. Estey E, Döhner H (2006) Acute myeloid leukaemia. Lancet 368:1894–1907

    Article  PubMed  Google Scholar 

  2. Ferrara F (2004) Unanswered questions in acute myeloid leukaemia. Lancet Oncol 5:443–450

    Article  PubMed  Google Scholar 

  3. Avivi I, Rowe JM (2005) Prognostic factors in acute myeloid leukemia. Curr Opin Hematol 12:62–67

    Article  CAS  PubMed  Google Scholar 

  4. Grimwade D (2001) The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 14:497–529

    Article  CAS  PubMed  Google Scholar 

  5. Byrd JC, Mrózek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336

    Article  CAS  PubMed  Google Scholar 

  6. Mrózek K, Marcucci G, Paschka P et al (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109:431–448

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mrózek K, Döhner H, Bloomfield CD (2007) Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 14:106–114

    Article  PubMed  Google Scholar 

  8. Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279:2610–2623

    Article  CAS  PubMed  Google Scholar 

  9. Kent C (2005) Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. Biochim Biophys Acta 1733:53–66

    Article  CAS  PubMed  Google Scholar 

  10. Shindou H, Shimizu T (2009) Acyl-CoA: lysophospholipid acyltransferases. J Biol Chem 284:1–5

    Article  CAS  PubMed  Google Scholar 

  11. Grupp K, Sanader S, Sirma H et al (2013) High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol 7:1001–1011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. He RQ, Li JD, Du XF et al (2021) LPCAT1 overexpression promotes the progression of hepatocellular carcinoma. Cancer Cell Int 21(1):442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sun Q, Liu X, Peng Q et al (2022) ncRNA-mediated high expression of LPCAT1 correlates with poor prognosis and tumor immune infiltration of liver hepatocellular carcinoma. J Immunol Res 2022:1584397

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ji W, Peng Z, Sun B et al (2021) LPCAT1 promotes malignant transformation of hepatocellular carcinoma cells by directly suppressing STAT1. Front Oncol 11:678714

    Article  PubMed  PubMed Central  Google Scholar 

  15. Morita Y, Sakaguchi T, Ikegami K et al (2013) Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol 59:292–299

    Article  CAS  PubMed  Google Scholar 

  16. Shen L, Gu P, Qiu C et al (2022) Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway. Ann Hepatol 27(3):100680

    Article  CAS  PubMed  Google Scholar 

  17. Lebok P, von Hassel A, Meiners J et al (2019) Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging (Albany NY) 11:7796–7804

    Article  CAS  PubMed  Google Scholar 

  18. Abdelzaher E, Mostafa MF (2015) Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence. Tumour Biol 36:5473–5483

    Article  CAS  PubMed  Google Scholar 

  19. Zhao T, Zhang Y, Ma X et al (2021) Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer. Cancer Cell Int 21(1):269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Shida-Sakazume T, Endo-Sakamoto Y, Unozawa M et al (2015) Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor. PLoS ONE 10:e0120143

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tao M, Luo J, Gu T et al (2021) LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma. Cell Death Dis 12(9):845

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Huang Y, Wang Y, Wang Y et al (2022) LPCAT1 promotes cutaneous squamous cell carcinoma via EGFR-mediated protein kinase B/p38MAPK signaling pathways. J Invest Dermatol 142(2):303-313.e9

    Article  CAS  PubMed  Google Scholar 

  23. Wei C, Dong X, Lu H et al (2019) LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway. J Exp Clin Cancer Res 38:95

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ding J, Ding X, Leng Z (2022) LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma. J Cancer 13(6):1837–1847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Yin C, Zhang J, Guan W et al (2021) High expression of CLEC11A predicts favorable prognosis in acute myeloid leukemia. Front Oncol 11:608932

    Article  PubMed  PubMed Central  Google Scholar 

  26. Bagger FO, Sasivarevic D, Sohi SH et al (2016) BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res 44:D917–D924

    Article  CAS  PubMed  Google Scholar 

  27. Bennett JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620–625

    Article  CAS  PubMed  Google Scholar 

  28. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302

    Article  CAS  PubMed  Google Scholar 

  29. Lo Coco F, Foa R (1995) Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol 55:1–9

    Article  CAS  PubMed  Google Scholar 

  30. Slovak ML, Kopecky KJ, Cassileth PA et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075–4083

    Article  CAS  PubMed  Google Scholar 

  31. Lin J, Yao DM, Qian J et al (2012) IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 91:519–525

    Article  CAS  PubMed  Google Scholar 

  32. Lin J, Yao DM, Qian J et al (2011) Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 6:e26906

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Yang X, Qian J, Sun A et al (2013) RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. Clin Biochem 46:579–583

    Article  CAS  PubMed  Google Scholar 

  34. Qian J, Yao DM, Lin J et al (2012) U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 7:e45760

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wen XM, Lin J, Yang J et al (2014) Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol 7:6832–6840

    PubMed  PubMed Central  Google Scholar 

  36. Wang K, Wu Z, Si Y et al (2021) Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia. Oncol Lett 21:105

    Article  CAS  PubMed  Google Scholar 

  37. Abdelzaher Ahmed E, Abdel Bary Abdel-Latif A, Fahmy AM et al (2021) Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas. J Histotechnol 44(4):196–205

    Article  CAS  PubMed  Google Scholar 

  38. Pabst T, Kortz L, Fiedler GM et al (2017) The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin 7:105–114

    Article  PubMed  PubMed Central  Google Scholar 

  39. Gottfried EL (1967) Lipids of human leukocytes: relation to celltype. J Lipid Res 8(4):321–327

    Article  CAS  PubMed  Google Scholar 

  40. Zhou JD, Zhang TJ, Xu ZJ et al (2020) Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes. Cell Death Dis 11:997

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Taby R, Issa JP (2010) Cancer epigenetics. CA Cancer J Clin 60:376–392

    Article  PubMed  Google Scholar 

  42. Yamashita K, Hosoda K, Nishizawa N et al (2018) Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment. Cancer Sci 109:3695–3706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by National Natural Science foundation of China (81970118), the Youth Medical Talents Project of “Ke Jiao Qiang Wei” project of Jiangsu province (QNRC2016449), and Zhenjiang Clinical Research Center of Hematology (SS2018009).

Author information

Authors and Affiliations

  1. Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, People’s Republic of China

    Qin Chen, Zijun Xu, Jiang Lin, Zhaoqun Deng & Wei Qian

  2. Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, People’s Republic of China

    Jun Qian

  3. Department of Otolaryngology-Head and Neck Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, People’s Republic of China

    Wei Qian

Authors
  1. Qin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zijun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhaoqun Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study’s conception and design. Material preparation, data collection and analysis were performed by Qin Chen, Zijun Xu, and Jiang Lin. The first draft of the manuscript was written by Qin Chen and Zhaoqun Deng. The manuscript revision was conducted by Jun Qian and Wei Qian. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Jun Qian or Wei Qian.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

This study was conducted in compliance with the 1964 Helsinki declaration and was approved by the Ethics Committee of the Affiliated People’s Hospital of Jiangsu University (No. K-20180063-Y).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Q., Xu, Z., Lin, J. et al. The validation and clinical significance of LPCAT1 down-regulation in acute myeloid leukemia. Mol Biol Rep 50, 4955–4963 (2023). https://doi.org/10.1007/s11033-023-08449-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-023-08449-7

Keywords

Search

Navigation